Generating Molecules with the Help of Recurrent Neural Networks

In 2017, the "digital medicine" Spinraza was released to the public, after years of drug development to cure Spinal Muscular Atrophy (SMA), at a price of $750,000 initially and $375,000 annually after that. The cause of SMA was a simple mutation on the SMN1 gene on chromosome 5. One altered nucleotide sequence in the exon of the SMN1 gene changed the complete life trajectory for children born with this disease, many dying before the end of infancy. However, the price of pharmaceutical drug, which many government's and insurance companies refuse to pay, has left children unable to acquire treatment. All the medicine simply does, is takes the reverse compliment sequence of a neighbouring intronic sequence, and binds to it.